Core Insights - Talphera, Inc. reported its fourth quarter and full year 2025 financial results, highlighting significant progress in its NEPHRO CRRT clinical study and financial position [1][2][3] Financial Performance - The company reported a net loss of $3.8 million for Q4 2025, equating to $0.06 per share, compared to a net loss of $1.9 million or $0.07 per share in Q4 2024 [4][14][18] - Total operating costs and expenses for Q4 2025 were $3.5 million, up from $3.0 million in Q4 2024, primarily due to increased R&D and G&A expenses [4][14][20] - Cash and investments stood at $20.4 million as of December 31, 2025, a significant increase from $8.9 million at the end of 2024 [4][19] Clinical Development - Talphera achieved a 50% enrollment milestone in the NEPHRO CRRT study, with 35 patients enrolled out of a target of 70 [2][4][11] - All 12 clinical sites are now operational for patient enrollment, which is expected to accelerate the study's completion by 2026 [1][4] - The NEPHRO CRRT study aims to evaluate the efficacy of Niyad, a formulation of nafamostat, as an anticoagulant in patients undergoing renal replacement therapy [10][11] Future Guidance - The company anticipates cash operating expenses in the range of $17 million to $18 million for 2026, driven by the NEPHRO CRRT study and related expenses [3][5] - A virtual investor and analyst day is scheduled for March 23, 2026, to provide updates on the company's progress and insights from principal investigators involved in the NEPHRO CRRT study [1][6]

Core Insights - Talphera, Inc. will host a virtual investor and analyst event on March 23, 2026, to discuss Niyad® for continuous renal replacement therapy (CRRT) [1] - The event will feature principal investigators from the NEPHRO CRRT study, which evaluates Niyad's efficacy [1][2] Company Overview - Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for medically supervised settings [9] - The lead product candidate, Niyad, is a lyophilized formulation of nafamostat, which has received Breakthrough Device Designation from the FDA [9] Product and Study Details - Nafamostat is a broad-spectrum serine protease inhibitor with anticoagulant, anti-inflammatory, and potential antiviral properties, used in CRRT for over 30 years in Japan and South Korea [2] - Niyad aims to serve as a regional anticoagulant for patients who cannot tolerate heparin or are at risk of bleeding, addressing limitations of current anticoagulants [2] - The NEPHRO CRRT study is a prospective, double-blinded trial enrolling 70 adult patients in U.S. ICUs, focusing on the mean post-filter activated clotting time as the primary endpoint [7] Expert Involvement - Blaithin McMahon, PhD, and Joao Teixeira, MD, are principal investigators with extensive backgrounds in nephrology and critical care, contributing to the study's credibility [4][5]

Core Insights - Talphera, Inc. closed a $17 million first tranche financing led by CorMedix, which is expected to provide sufficient capital through a potential PMA approval of Niyad anticipated in late 2026 [1][2] - The NEPHRO study, which is crucial for the development of Niyad, is progressing with 5 of the 9 target clinical sites activated, and completion is expected in the first half of 2026 [1][2][12] Financial Highlights - As of September 30, 2025, Talphera reported cash and investments totaling $21.3 million [1][6] - The combined R&D and SG&A expenses for Q3 2025 were $3.4 million, a decrease from $3.7 million in Q3 2024, primarily due to reductions in personnel and other expenses [6][15] - The net loss from continuing operations for Q3 2025 was $4.4 million, compared to a net loss of $3.4 million in Q3 2024 [6][15] Clinical Development - The NEPHRO CRRT study is designed to evaluate Niyad as an anticoagulant for patients undergoing renal replacement therapy, with a primary endpoint focused on mean post-filter activated clotting time [12][11] - Positive feedback from principal investigators indicates a strong preference for nafamostat as an alternative to current CRRT anticoagulants, contributing to ongoing enrollment momentum in the NEPHRO study [2][12] Strategic Partnerships - CorMedix's investment includes the right to nominate a board member and an exclusive negotiation period for a potential acquisition following the Phase 3 study results for Niyad [6][2] - The financing round also included support from existing investors and new institutional investors, highlighting the market opportunity for Niyad [2][6]